DALLAS–(BUSINESS WIRE)–Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of TRDALLAS–(BUSINESS WIRE)–Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of TR

Generational Group Advises TR Chem Solutions, LLC in Its Sale to FBC Chemical Corporation

2025/12/23 02:31
3 min read

DALLAS–(BUSINESS WIRE)–Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of TR Chem Solutions, LLC to FBC Chemical Corporation. The acquisition closed October 31, 2025.

TR Chem Solutions, LLC is a specialty chemical manufacturer and supplier that develops advanced processing chemicals for a wide range of industrial uses. The company draws on extensive manufacturing experience to formulate and deliver high quality products that support customer production schedules and improve performance in applications such as food processing, automotive polishes and dressings, inks, coatings, bottling lubricants, plastic recycling, release agents, and cleaning products. TR Chem Solutions’ portfolio includes silicone fluids, specialty silicone additives, non-silicone dressings, industrial emulsions and antifoams, and food-grade lubricants, with an emphasis on innovation and responsive service.

Based in Mars, Pennsylvania, FBC Chemical Corporation is a full service chemical distributor that provides bulk, tote and drum quantities of organic and inorganic chemicals to a broad range of industries, including cleaning, coatings, agriculture, metalworking, personal care, pharmaceuticals, water treatment, and energy. The company operates multiple warehousing and distribution centers with climate-controlled storage, its own delivery fleet, rail access and laboratory support to ensure reliable, just-in-time supply and technical assistance for its customers. FBC Chemical also offers toll blending and custom services and emphasizes customer satisfaction, rapid delivery and long-term partnerships with both suppliers and clients.

Generational Group Executive Managing Director, M&A, Central Region—Michael Goss—and his team led by Senior Vice President, M&A, Jon LePage successfully closed the deal. Senior Managing Director, Thomas Hamm, and Senior M&A Advisor, Michael Lorence, established the initial relationship with TR Chem Solutions, LLC.

“TR Chem Solutions and FBC Chemical Corporation form a terrific partnership and represent a win-win outcome for customers, suppliers, and employees across the board. This strategic acquisition expands FBC’s market reach and strengthens its supplier network with the addition of several premium manufacturers,” said Senior Vice President, M&A, Jon LePage.

Ryan Binkley, CEO of Generational Group, added, “This transaction shows our dedication to meaningful, long-term partnerships. It brings together partners who share a common vision and are ready to continue their growth together.”

About Generational Group

Generational Group, headquartered in Dallas, TX, is a leading, award winning full-service M&A advisory firm. Generational has over 300 professionals across 16 offices in North America. The firm empowers business owners to unlock the full value of their companies through a comprehensive suite of services—including strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A advisory, digital solutions, and wealth management.

Celebrating its 20th year, Generational has successfully closed over 1,800 transactions and has ranked #1 or #2 in all LSEG league tables for deals valued between $25 million and $1 billion in 2022, 2023, and 2024.

The firm was named 2025 USA Investment Banking Firm of the Year by the Global M&A Network and recognized as Investment Banking Firm of the Year by The M&A Advisor in 2022, 2024, and 2025.

Contacts

Media Contact:

Catherine Binkley

469-828-2798

cbinkley@generational.com

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03